With an innovative approach to treating heart failure, Cytokinetics touted a game-changing medicine that could someday become available for an elusive condition that effects more than 6 million in the U.S.
But that hope is flickering. In a complete response letter (CRL) to Cytokinetics on Tuesday, the FDA rejected the application for approval of heart failure candidate omecamtiv mecarbil.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,